Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Regorafenib for Recurrent Meningioma. A Multicenter, Randomized Phase II Study (MIRAGE Trial)

NCT06275919 is registered in ClinicalTrials.gov with Istituto Oncologico Veneto IRCCS as lead sponsor.

NCT NCT06275919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06275919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Regorafenib for Recurrent Meningioma. A Multicenter, Randomized Phase II Study (MIRAGE Trial)
Lead sponsor
Istituto Oncologico Veneto IRCCS
Phase
Phase 2
Overall status
Recruiting
Start date
September 23, 2024
Completion date
March 31, 2029
Enrollment
104 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

meningioma, malignant